Prostate cancer is the most commonly diagnosed cancer in men worldwide, which represents over 1.4 million new cases each year. For many patients, radiotherapy is a typical treatment option that offers results comparable to surgery, especially for localized diseases. As a process of external patients, it allows men to maintain much of their daily routine during treatment. However, traditional radiotherapy schedules usually cover several weeks, which may be burdensome for patients and exert pressure on healthcare structures and radiotherapy.
An important clinical trial (Hypo-RT-PC) has shown that a significantly shorter radiotherapy course for localized prostate cancer is just as safe and effective as the eight-week traditional program-even 10 years after treatment. The findings, presented at Estro 2025, the European Conference of the European Society for Radiotherapy and Oncology, give patients and doctors more confidence in choosing this short course approach, also called “hyper-hypothesis”.
The study, led by researchers in Sweden, found that the provision of precision radiotherapy in just two and a half weeks is equally successful in beating prostate cancer as the standard approach of eight weeks. A decade after treatment, both options produced similar rates of disease control and survival.
“These long-term findings confirm the previous 5-year results from the test, showing that providing fewer, higher doses in a shorter period works just like the standard approach-not only in theory, but in real clinical practice,” concluded by Nilson and Nilsson, which led the 10-year analysis of Hypo-RT-RT-RT-RT-R-RT-R University Hospital Skåne and Lund University, Sweden.
“For patients, this means less disorder in everyday life and possibly a reduction in healthcare costs – without at stake results and safety.”
For the study
This large Phase III clinical trial was recorded 1,200 men located with intermediate to high risk of prostate cancer. Participants were randomly assigned to receive either:
• Short -run radiotherapy: 42.7 Gray (GY) delivered to 7 sessions for 2.5 weeks
• Standarded Radiotherapy: 78.0 GY was delivered to 39 sessions for 8 weeks
Researchers evaluated the side effects of survival, cancer recurrence and treatment associated, including symptoms of urine and intestinal.
Basic results after 10 years:
• Survival without failure (no cancer refund or need for additional treatment): 72% in the short -run group versus 65% in the standard group
• Total survival: 81% for short circuit versus 79% for the standard
• Prostate cancer mortality: 4% in both groups
• Side effects: The symptoms of urine and bowel were similar in both groups and most were mild to moderate.
“These findings confirm that the shorter course does not increase the long -term side effects and provides equally durable cancer control“, added Camilla Thellenberg-Karlsson, MD, PhD, at Umeå University, who presented the results at the Estro meeting.
Impact on cancer care
Prostate cancer is one of the most common cancers in men and radiotherapy remains a basic treatment. These results show how modern radiotherapy approaches can make treatment more effective, accessible and patient -friendly – without sacrificing efficacy or safety.
Professor Matthias Gucenberger, president of Estro, added: “The shortest treatment programs mean that patients can return to their normal lives faster.
“Reduction of treatment time in just two and a half weeks is an important victory for both patients and health systems.
“This study is an example of the kind of aggressive research that changes practice we are proud of at Estro 2025.”
